

Key updates to the Buckinghamshire Formulary* January 2020

www.bucksformulary.nhs.uk

Green	Aerochamber Plus Flow-Vu® spacer device	CE marked medical device
<p>Anti-static spacers reduce deposition of aerosolized small particles on the spacer wall leading to more reliable drug delivery to the lungs. Unlike the Aerochamber Plus® spacer, the Aerochamber Plus Flow-Vu® is anti-static, does not need priming before use, is dishwasher safe and has a visual tool to help count breaths. It is included on the formulary: For administration of aerosolized medication from pMDI inhalers for asthma and COPD.</p> <ul style="list-style-type: none"> As 1st line spacer for new patients To replace the Aerochamber Plus® spacer for all existing users at annual review. 		
Green / Amber initiation	Management of Gout guideline (updated)	Licensed
<p>This reflects updates to BSR and EULAR guidance. A key message in the guideline is the need for Urate Lowering Therapy (ULT) to be titrated to maintain serum uric acid levels at or below a target level of <0.3 mmol/L. Febuxostat contraindications (ischaemic heart disease, CCF) are also emphasized. http://www.bucksformulary.nhs.uk/docs/Guideline_777FM.pdf?uid=597747333&uid2=2020113144553150</p>		
Green	SGLT2 inhibitors for type 2 diabetes	Licensed
<p>Ertugliflozin has been added to the formulary. In line with ADA/EASD and SIGN recommendations, the choice of an SGLT2 inhibitor should take into account evidence of cardiovascular benefit: The choice of SGLT2 inhibitors on the Bucks formulary are: For glycaemic control in patients with established cardiovascular disease (CVD)</p> <ul style="list-style-type: none"> 1st line: Empagliflozin or canagliflozin; 2nd line: Dapagliflozin <p>For glycaemic control in patients without established cardiovascular disease (CVD)</p> <ul style="list-style-type: none"> 1st line: Empagliflozin or canagliflozin; 2nd line: Dapagliflozin or ertugliflozin <p>The Type 2 Diabetes Blood glucose lowering guideline has been updated accordingly. http://www.bucksformulary.nhs.uk/docs/Guideline_667FM.pdf?uid=128666096&uid2=2019930145145175</p>		
Green	GLP-1 agonists for type 2 diabetes	Licensed
<p>Semaglutide and dulaglutide have been added to the formulary. In line with ADA/EASD and SIGN recommendations, the choice of a GLP-1 agonist should take into account evidence of cardiovascular benefit. The Bucks formulary choice of a GLP-1 agonist for new patients is as follows: For glycaemic control in patients with established atherosclerotic cardiovascular disease (ASCVD)</p> <ul style="list-style-type: none"> 1st line: Liraglutide 1.8 mg once daily; 2nd line: Semaglutide once weekly; 3rd line: Dulaglutide once weekly. <p>For glycaemic control in patients without established ASCVD:</p> <ul style="list-style-type: none"> 1st line: Semaglutide once weekly; 2nd-line: Dulaglutide once weekly; 3rd-line: Liraglutide 1.2 mg once daily <p>Existing patients achieving glycaemic control and weight loss targets remain on Exenatide twice daily or one weekly. If not controlled, the choice of GLP-1 agonists for new patients applies. The GLP-1 agonists guideline has been updated to reflect these changes. http://www.bucksformulary.nhs.uk/docs/Guideline_109FM.pdf?uid=597747606&uid2=2020113144838247</p>		
Green	Blood glucose meters and test strips	Licensed medical devices
<p>A local review of blood glucose meters and test strips has identified cost effective 'preferred' blood glucose meters and 'alternative' meters to meet the needs of specific patient groups. http://www.bucksformulary.nhs.uk/docs/Guideline_212FM.pdf?uid=430182870&uid2=201912117502324</p>		

Key updates to the Buckinghamshire Formulary* January 2020

www.bucksformulary.nhs.uk

Green	DPP-4 inhibitors (Gliptins) for type 2 diabetes	Licensed
<ul style="list-style-type: none"> 1st line: Sitagliptin 100mg daily 2nd line: Linagliptin for renal impairment (eGFR <60ml/min/1.73m²) and declining renal function. Linagliptin has been added to the formulary because it does not require dose adjustment in renal impairment. 		
Green	Microdot insulin safety needles	Licensed medical device
<p>1st line insulin safety needle used to enable insulins and GLP-1 agonists available in pre-filled pens to be given safely by a third party when patients are unable to self-administer. Use in BHT has to be authorised for named patients by a Diabetes Specialist Nurse (DSN) so that staff training about use of the safety needles is assured</p>		
Green / Amber Recommendation	Skeletal muscle relaxants for treatment of spasticity: Baclofen, dantrolene and tizanidine	Licensed
<ul style="list-style-type: none"> 1st line; Baclofen tablets and oral solution (Green) 2nd line: Dantrolene tablets. (Green) or Tizanidine tablets (Amber Recommendation) <p>LFT monitoring</p> <ul style="list-style-type: none"> Dantrolene and tizanidine require baseline LFTs. Tizanidine needs monthly LFTs for the first four months. Dantrolene needs LFT monitoring at intervals (according to the SPC). Baseline and ongoing LFTs to be undertaken by the Specialist. In exceptional circumstances, e.g. if the patient cannot attend hospital, the Specialist will provide clear, timely written instructions to the GP to confirm the requirements for baseline and ongoing LFT monitoring 		
Amber Recommendation	Dapagliflozin with insulin for type 1 diabetes	Licensed
<p>For treatment of Type 1 Diabetes as an adjunct to insulin in accordance with NICE TA 597 Initiation on the recommendation of consultant Diabetologists, continuation by GPs.</p>		
Amber Recommendation / Red	COMT inhibitors: Entacapone, Opicapone and Tolcapone for Parkinson's disease	Licensed
<ul style="list-style-type: none"> 1st line; Entacapone (Amber recommendation) 2nd line: Opicapone for patients with end of dose motor fluctuations/OFF periods who are unsuitable for entacapone due to its inefficacy or intolerance. (Amber recommendation) 3rd line: Tolcapone (red) due to hepatotoxicity and need for very frequent LFT monitoring 		
Amber Recommendation	Anal irrigation systems for bowel dysfunction	Licensed
<p>Peristeen transanal irrigation system®, Aquaflush Compact® Monthly set, Qufora Irrisedo Mini® monthly set, Aquaflush Lite® monthly set, Aquaflush Quick®, Qufora Irrisedo Cone Toilet System®, Navina Classic®, IryPump S®, Navina Smart®, Qufora® IrriSedo Bed system Are approved for formulary inclusion as follows:</p> <ul style="list-style-type: none"> For management of bowel dysfunction in accordance with TVPC policy 3a Anal Irrigation Systems for the Management of Faecal Incontinence/ constipation Initiation on the recommendation of Specialist Continence Nurse led bowel management service or Specialist in bowel management. Continuation by GPs 		
Amber Initiation	Adjuvant bisphosphonates for early breast cancer: zoledronic acid and ibandronic acid Amber Initiation guideline.	Licensed
<p>Oral ibandronic acid has been added to the Bucks formulary for this indication. A new Bucks amber initiation guideline has been produced to support local implementation of NICE CG 101 http://www.bucksformulary.nhs.uk/docs/Guideline_834FM.pdf?UNLID=5977479802020113145544</p>		

Key updates to the Buckinghamshire Formulary* January 2020

www.bucksformulary.nhs.uk

Amber initiation	Liothyronine	Licensed
<p>Guidance to support review of prescribing of liothyronine is provided in a Bucks Liothyronine review algorithm. http://www.bucksformulary.nhs.uk/docs/Guideline_725FM.pdf?uid=128666096&uid2=2019930145145312</p>		
Amber Protocol	Premature Ovarian Insufficiency (POI)	Licensed
<p>The POI guideline depicts the relative place of HRT, progesterones and testosterone gels. A shared care protocol for the use of testosterone gels for POI has also been produced. http://www.bucksformulary.nhs.uk/docs/Guideline_422FM.pdf?uid=128666096&uid2=2019930145145316</p>		
Amber Protocol	Methotrexate shared care protocol (updated)	Licensed
<p>Revised to reflect updated DMARD prescribing guidance from the BSR which aims to align the monitoring timing for DMARDs. http://www.bucksformulary.nhs.uk/docs/Guideline_794FM.pdf?uid=430182870&uid2=20191211750218</p>		
Amber Protocol	Riluzole for Motor Neurone Disease (MND) col	Licensed
<p>A new shared care protocol for riluzole use in motor neurone disease (MND) has been approved http://www.bucksformulary.nhs.uk/docs/Guideline_784FM.pdf?uid=128666096&uid2=2019930145145317</p>		
Red	Dual antiplatelet therapy (DAPT) for specific cohorts of stroke/TIA patients	Licensed
<p>Dual antiplatelet therapy (DAPT) (aspirin and clopidogrel) has been approved as follows:</p> <ul style="list-style-type: none"> For minor ischaemic (non-cardio-embolic) stroke and definite / probable TIA: 3 weeks' DAPT For intracranial stenosis: 3 months' DAPT <p>DAPT is prescribed by Secondary care before GPs take over prescribing of single antiplatelet therapy. . The Discharge Summary / letters and hospital Pharmacy medicine labels record the stop date for DAPT and this is reinforced via counselling of patients. The hospital supplies the full course of DAPT. The Bucks Antiplatelet therapy guideline has been updated to reflect these changes http://www.bucksformulary.nhs.uk/docs/Guideline_708FM.pdf?uid=597748666&uid2=202011315252140</p>		
Red	Biologics and immunomodulatory drugs for psoriasis	Licensed
<p>The algorithm has been updated to incorporate Certolizumab (NICE TA 574), Guselkumab (NICE TA 521), Brodalumab (NICE TA 511) and Tildrakizumab (NICE TA 575) http://www.bucksformulary.nhs.uk/docs/Guideline_738FM.pdf?uid=128666096&uid2=2019930145145168</p>		
Red	Biologics and immunomodulatory drugs in rheumatoid arthritis	Licensed
<p>The algorithm has been updated to incorporate rituximab monotherapy, sequential use of biologics following an adverse reaction and to align more closely with Thames Valley Priorities Committee policy TVPC51 http://www.bucksformulary.nhs.uk/docs/Guideline_749FM.pdf?uid=128680693&uid2=20199301668170</p>		
Red	Biologics and immunomodulatory drugs in Ulcerative colitis	Licensed
<p>The algorithm has been updated to incorporate tofacitinib (NICE TA 547) http://www.bucksformulary.nhs.uk/docs/Guideline_633FM.pdf?uid=430231118&uid2=2019121232825228</p>		
ABBREVIATIONS		
ADA / EASD	American Diabetes Association	European Association for the Study of Diabetes
BSR	British Society of Rheumatology	
CNS	Clinical Nurse Specialist	
COMT	Catechol-O-methyl-transferase	

Key updates to the Buckinghamshire Formulary* January 2020

www.bucksformulary.nhs.uk

DMARD	Disease Modifying Ant rheumatic drug
DAPT	Dual antiplatelet therapy
EULAR	European League against Rheumatism

Produced by the Medicines Resource Centre, Buckinghamshire Integrated Care Partnership

* For a full list of formulary changes, see the Formulary Decisions spreadsheet linked from the website home page